Treatment of Patients With Advanced Cancer Following Chemotherapy and Traditional Medicine - Long Term Follow Up of 75 Cases

Abstract

Objective: Traditional systems of medicine all over the world even traditional medicine and cancer have been using plants and plants products for therapeutic intention. The purpose of these retrospective trials is to assess the clinical efficacy of chemotherapy in conjunction with TCM for a broad variety of cancers. Methods: 75 patients with available cancers were concluded in the study during September1993 -May 2018.The sex ratio of male: female was 50:25 respectively. The mean age at onset was 46.9 years( range 10-79 years. All patients were treated with different dosage of various chemotherapy in combination with TCM or traditional medicine alone. The basic chemotherapeutic regimen consisted of vincristine( VCR, 1-2 mg/week)、 cyclophosphamide( CTX, 200-1, 000mg/ week), mitomycin C(MMC, 2-4mg/week) and 5-fluorouracil( 5-Fu,250-500mg/ day). The detail prescription of TCM varied among a broad variety of carcinomas. The criteria of complete remission( CR) and/or partial remission( PR) is according to the rules where physicians have in common with in clinics. In 75 cases, the CR was obtained in 33(44%) advanced cancers, a short CR in 11(14.7%) cases, PR in 25 (33.3%) cancers, stable disease in 6 cases.. The crude herbs consisted of sargassum, tangle, Oyster(mussels), Poria cocos, Ophiopogon japonicus, Prunella vulgaris, Taraxacum, Scrophularia ningpoensis, Cremastra appendiculata, Trichosanthes Kirilowii, Sophora subprostrata, Houttuynia cordata, Scutellaria barbata d. don and Oldenlandia diffusa roxb. Results: Among those long-term survivors, 31 carcinomas obtained in disease-free survival over 5 years, 20 cancers were survival over 10 years, the longest four patients over 25 years. Conclusion: In this study, it was experienced that a CR was a pivotal influencing factor in those longest survival patients, and traditional medicine was also recommended. Down regulating oncogenic receptors may be useful paradigm and perspective in currently the third line setting of clinical target therapy and in rendering our better understanding of cancer biology. Cite this article-George Zhu. Treatment of patients with advanced cancer following chemotherapy and traditional medicine -long term follow up of 75 cases. 16 CODEN (USA): UJPRA3 leukocytosis with development of retinoic acid syndrome, an important adverse reaction during treatment of APL. Thus, Tamibarotene demonstrated more efficacy in both untreated APL patients and relapsed who have been treated ATRA and chemotherapy, especially as novel strategy in relapsed APL in Japan and others 74-76 . This is encouraging perspective.

Vitamin A and its Derivatives- Retinoic Acid and Retinoid Pharmacology

“…Zhu [90] conduct a short CR using chemotherapy and topical 5% Fu of retinoic acid ointment in a 75-year old patient with SCC. She had a 8x5cm rodent ulcer in her left ear and facial area.…”

Target Oncogenic Receptors in Tumours, A Hot Topics Today

“…Since the discovery of oncogenic receptor by George Zhu from oncogenic pml/RARa fusion in the origin of a specific APL and androgen/oncogenic androgen receptor signaling in hormonal tumorigenesis in 1989s, many studies are dedicated on their clinical targeting therapy. At present, thousands of publications and over 100 global journals are focused on this area targeting oncogenic receptor or oncogenic receptor (tyrosine) kinase in tumours [1][2][3][4][5][6][7]. The traditionally accepted view is that normal epidermal growth factor receptor (EGFR) is no tumorigenic [8].…”